Perspective Therapeutics (NYSE:CATX) Earns Outperform Rating from Wedbush

Perspective Therapeutics (NYSE:CATX - Get Free Report)'s stock had its "outperform" rating reissued by equities researchers at Wedbush in a research note issued on Monday,Benzinga reports. They currently have a $11.00 target price on the stock. Wedbush's target price suggests a potential upside of 202.61% from the stock's current price.

CATX has been the topic of a number of other reports. Royal Bank Of Canada raised shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and lifted their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd. Brookline Capital Management raised Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Truist Financial lowered their price target on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Perspective Therapeutics in a report on Monday, March 31st. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $12.63.

Perspective Therapeutics Stock Up 5.1%

Shares of CATX stock traded up $0.18 on Monday, reaching $3.64. The company had a trading volume of 79,801 shares, compared to its average volume of 1,082,088. The business's 50-day moving average is $2.64 and its 200 day moving average is $2.83. Perspective Therapeutics has a one year low of $1.60 and a one year high of $16.55.

Insiders Place Their Bets

In other news, CFO Juan Graham purchased 33,333 shares of the business's stock in a transaction on Friday, March 28th. The stock was acquired at an average cost of $2.25 per share, for a total transaction of $74,999.25. Following the purchase, the chief financial officer now directly owns 35,354 shares in the company, valued at $79,546.50. This trade represents a 1,649.33% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert F. Williamson III purchased 22,192 shares of Perspective Therapeutics stock in a transaction dated Friday, March 28th. The shares were acquired at an average cost of $2.27 per share, with a total value of $50,375.84. Following the transaction, the director now directly owns 70,837 shares in the company, valued at approximately $160,799.99. The trade was a 45.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 115,696 shares of company stock worth $256,344. Company insiders own 3.72% of the company's stock.

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CATX. Y Intercept Hong Kong Ltd bought a new stake in shares of Perspective Therapeutics in the 4th quarter valued at approximately $33,000. Aigen Investment Management LP bought a new position in Perspective Therapeutics during the fourth quarter valued at $34,000. National Bank of Canada FI lifted its holdings in shares of Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after acquiring an additional 10,998 shares during the last quarter. ProShare Advisors LLC boosted its stake in shares of Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after purchasing an additional 5,011 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Perspective Therapeutics in the 4th quarter worth about $51,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.